• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TFE3 重排肾细胞癌的诊断与管理:病例报告及文献综述

Diagnosis and management of TFE3-rearranged renal cell carcinoma: case report and literature review.

作者信息

Zhang Yongxin, Shen Junxin, Wu Jinfeng, Huang Hongxing, Meng Fengjiao, Yuan Runqiang, Lu Yangbai

机构信息

Department of MR, Zhongshan City People's Hospital, Zhongshan, Guangdong, China.

Department of First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong, China.

出版信息

BMC Urol. 2025 Aug 20;25(1):207. doi: 10.1186/s12894-025-01908-2.

DOI:10.1186/s12894-025-01908-2
PMID:40836233
Abstract

BACKGROUND

TFE3-rearranged renal cell carcinoma is a rare malignancy with distinctive morphological and immunological characteristics. Although it can manifest in individuals of any age, its occurrence in adults is exceedingly uncommon, comprising only 1.5% of adult renal cell carcinomas. The disease typically presents with a benign course in pediatric patients, yet in adults, it often progresses rapidly and aggressively.

CASE PRESENTATION

Herein, we present a case of a 35-year-old female diagnosed with TFE3-rearranged renal cell carcinoma, who was initially asymptomatic. Imaging studies revealed a solid renal mass in the left kidney without signs of metastasis. Initially misdiagnosed as a vascular smooth muscle lipoma, the patient underwent laparoscopic partial nephrectomy. Subsequent histopathological and molecular analyses validated the diagnosis of TFE3-rearranged renal cell carcinoma. The patient demonstrated favorable short-term outcomes after early laparoscopic intervention, with no evidence of tumor recurrence or metastasis at both the 4-month and 15-month follow-ups.

CONCLUSIONS

This case serves as a valuable resource for oncologists involved in the diagnosis and management of TFE3-rearranged renal cell carcinoma.

摘要

背景

TFE3 重排性肾细胞癌是一种罕见的恶性肿瘤,具有独特的形态学和免疫学特征。尽管它可在任何年龄的个体中出现,但其在成人中的发生极为罕见,仅占成人肾细胞癌的 1.5%。该疾病在儿科患者中通常表现为良性病程,但在成人中,它往往进展迅速且具有侵袭性。

病例报告

在此,我们报告一例 35 岁女性被诊断为 TFE3 重排性肾细胞癌,该患者最初无症状。影像学检查显示左肾有一个实性肿块,无转移迹象。该患者最初被误诊为血管平滑肌脂肪瘤,随后接受了腹腔镜部分肾切除术。随后的组织病理学和分子分析证实了 TFE3 重排性肾细胞癌的诊断。早期腹腔镜干预后,患者显示出良好的短期预后,在 4 个月和 15 个月的随访中均无肿瘤复发或转移的迹象。

结论

该病例为参与 TFE3 重排性肾细胞癌诊断和管理的肿瘤学家提供了宝贵的参考资料。

相似文献

1
Diagnosis and management of TFE3-rearranged renal cell carcinoma: case report and literature review.TFE3 重排肾细胞癌的诊断与管理:病例报告及文献综述
BMC Urol. 2025 Aug 20;25(1):207. doi: 10.1186/s12894-025-01908-2.
2
[Clinicopathological features and survival analysis of -rearranged renal cell carcinoma with venous tumor thrombus].[伴有静脉瘤栓的 - 重排肾细胞癌的临床病理特征及生存分析]
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Aug 18;57(4):650-661. doi: 10.19723/j.issn.1671-167X.2025.04.004.
3
Varieties of altered TFE3 can occur in MiT-family-related renal cell carcinomas.多种改变的TFE3可出现在与MiT家族相关的肾细胞癌中。
Int Urol Nephrol. 2025 Feb 18. doi: 10.1007/s11255-025-04394-5.
4
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and Adolescents.儿童和青少年TFE3重排肾细胞癌的分子特征
Mod Pathol. 2025 Jun;38(6):100748. doi: 10.1016/j.modpat.2025.100748. Epub 2025 Mar 6.
5
TFE3 -Rearranged PEComa/PEComa-like Neoplasms : Report of 25 New Cases Expanding the Clinicopathologic Spectrum and Highlighting its Association With Prior Exposure to Chemotherapy.TFE3 重排的上皮样血管平滑肌脂肪瘤/上皮样血管平滑肌脂肪瘤样肿瘤:25 例新病例的临床病理谱扩大及强调其与先前化疗暴露相关的报告。
Am J Surg Pathol. 2024 Jul 1;48(7):777-789. doi: 10.1097/PAS.0000000000002218. Epub 2024 Apr 10.
6
Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.XP11.2易位/TFE3基因融合性肾细胞癌的临床特征:一项观察性研究的系统评价和荟萃分析
BMC Urol. 2016 Jul 11;16(1):40. doi: 10.1186/s12894-016-0154-6.
7
Malignant tumors in tuberous sclerosis complex: a case report and review of the literature.结节性硬化症中的恶性肿瘤:病例报告及文献复习。
BMC Med Genomics. 2024 May 27;17(1):144. doi: 10.1186/s12920-024-01913-8.
8
Bilateral, multicystic fumarate hydratase-deficient renal cell carcinoma in patient with hereditary leiomyomatosis & renal cell carcinoma syndrome: A case report and review of the literature.遗传性平滑肌瘤病和肾细胞癌综合征患者的双侧多囊性富马酸水合酶缺乏性肾细胞癌:一例报告并文献复习
Diagn Pathol. 2025 Aug 26;20(1):99. doi: 10.1186/s13000-025-01706-2.
9
Clinically Sporadic Folliculin-mutated Renal Epithelial Neoplasms Represent a Mixture of True Somatic Folliculin-mutated and Occult Birt-Hogg-Dubé Syndrome-associated Cases: Morphologic and Molecular Overlap With TSC/MTOR-mutated Eosinophilic Renal Neoplasms and MiT Family Translocation Renal Cell Carcinoma.临床散发性卵泡抑素突变型肾上皮肿瘤代表真正的体细胞卵泡抑素突变病例与隐匿性Birt-Hogg-Dubé综合征相关病例的混合:与TSC/MTOR突变的嗜酸性肾肿瘤和MiT家族易位性肾细胞癌的形态学和分子学重叠
Am J Surg Pathol. 2025 May 5. doi: 10.1097/PAS.0000000000002413.
10
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.部分肾切除术与根治性肾切除术治疗 T1b 和 T2 期临床肾肿瘤的比较:系统评价和荟萃分析。
Eur Urol. 2017 Apr;71(4):606-617. doi: 10.1016/j.eururo.2016.08.060. Epub 2016 Sep 7.

本文引用的文献

1
Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinoma.透明细胞肾细胞癌分级系统的转录组学和蛋白质代谢决定因素
Urol Oncol. 2025 Mar 12. doi: 10.1016/j.urolonc.2025.02.016.
2
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and Adolescents.儿童和青少年TFE3重排肾细胞癌的分子特征
Mod Pathol. 2025 Jun;38(6):100748. doi: 10.1016/j.modpat.2025.100748. Epub 2025 Mar 6.
3
TFE3 fusion proteins promote the progression of TFE3 rearranged renal cell carcinoma via enhancing chaperone-mediated lipophagy.
TFE3融合蛋白通过增强伴侣介导的自噬促进TFE3重排肾细胞癌的进展。
Cell Commun Signal. 2025 Mar 6;23(1):122. doi: 10.1186/s12964-025-02117-y.
4
HIF1α Plays a Crucial Role in the Development of TFE3-Rearranged Renal Cell Carcinoma by Orchestrating a Metabolic Shift Toward Fatty Acid Synthesis.缺氧诱导因子1α通过调控向脂肪酸合成的代谢转变,在TFE3重排肾细胞癌的发展中起关键作用。
Genes Cells. 2025 Jan;30(1):e13195. doi: 10.1111/gtc.13195.
5
Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma.TFE3 重排型肾细胞癌的全面分子特征分析。
Exp Mol Med. 2024 Aug;56(8):1807-1815. doi: 10.1038/s12276-024-01291-2. Epub 2024 Aug 1.
6
The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery.脂质代谢在前列腺癌和肾癌中的阴暗面:分子诊断和生物标志物发现的新见解。
Expert Rev Mol Diagn. 2023 Apr;23(4):297-313. doi: 10.1080/14737159.2023.2195553. Epub 2023 Mar 28.
7
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.肾细胞癌作为一种代谢疾病:主要途径、潜在生物标志物和治疗靶点的最新研究进展。
Int J Mol Sci. 2022 Nov 18;23(22):14360. doi: 10.3390/ijms232214360.
8
The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cells.Abl2 酪氨酸激酶与 TGFβ1 信号通路的串扰调节透明细胞肾细胞癌细胞的侵袭。
FEBS Lett. 2023 Apr;597(8):1098-1113. doi: 10.1002/1873-3468.14531. Epub 2022 Nov 15.
9
Rearrangement and Expression in Renal Cell Carcinoma.肾细胞癌中的重排与表达。
Int J Surg Pathol. 2023 Aug;31(5):509-520. doi: 10.1177/10668969221108517. Epub 2022 Aug 1.
10
MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.MiTF/TFE 易位性肾细胞癌:从临床实体到分子见解。
Int J Mol Sci. 2022 Jul 11;23(14):7649. doi: 10.3390/ijms23147649.